dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Hematopoietic prostaglandin D synthase protein, also known as Glutathione-Dependent PGD Synthase, is a protein that in humans is encoded by the HPGDS gene. HPGDS is a bifunctional enzyme. One of its functions is to act as a Prostaglandin-D synthase by catalyzing the conversion of PGH2 to PGD2. As part of this, it plays a role in the production of prostanoids in the immune system and mast cells. It is also a sigma class glutathione-S-transferase family member, and so its other function is to catalyze the conjugation of glutathione by certain aryl halides and isothiocyanates. The presence of this enzyme can be used to identify the differentiation stage of human megakaryocytes.
=== Pharmacokinetics === The oral bioavailability of setipiprant is 44% in rats and 55% in dogs, which suggests that it should be orally bioavailable in humans. The half-life of setipiprant in humans is about 11 hours. The maximum concentration in plasma (Cmax) is 6.04 and 6.44 mcg/mL for setipiprant tablets and capsules respectively, with an area under the curve of 31.88 and 31.50 mcg×hours/mL for setipiprant tablets and capsules respectively. Cmax was reached between 1.8–4 hours after oral administration. The tablet and capsule formulations are bioequivalent.
== Corporate culture == S. Truett Cathy was a devout Southern Baptist; his religious beliefs had a major impact on the company. The company's official statement of corporate purpose says that the business exists "To glorify God by being a faithful steward of all that is entrusted to us. To have a positive influence on all who come in contact with Chick-fil-A." Cathy opposed the company becoming public for religious and personal reasons. A company spokesperson said in 2012, "The Chick-fil-A culture and service tradition in our Restaurants is to treat every person with honor, dignity, and respect –regardless of their belief, race, creed, sexual orientation, or gender."
=== French === Union Saint-Jean-Baptiste - Founded March 27, 1900 in Woonsocket, Rhode Island, as the Union Saint-Jean-Baptiste d'Amerique for Roman Catholic Franco-Americans. Activities include hospital volunteer work, comforting the bereaved, visiting shut-ins, and working in Catholic Action. The Saint-Jean-Baptiste Educational Foundation provides scholarships; the group also helps fund the Catholic Communications Foundation whose mission was to spread understanding of the Catholic faith and doctrine in the mass media. Headquarters was Woonsocket. The motto is "In Union there is strength". Lodges are called local councils, and the national convention is "National Congress". There was a ritual for initiation and the installation of officers. 62,000 members in 1968, 47,000 in January 1979. Merged with Catholic Family Life in 1991. Association Canado-Americaine - Founded in 1896 in Manchester, New Hampshire, which remained the organization's headquarters. Lodges were called Courts, regions District Courts, highest body "Supreme Court" which met quadrennially. A "High Court" administered the group in between sessions of the Supreme Court and determined district boundaries. Motto: "Religion, Patriotism, and Fraternity." The Association had rituals for initiation, installation, and other rites; the rituals reflected the Catholic values of the society whose patron was St. John the Baptist. The organization offered beneficiary and social membership; the former consisted of adult and infant divisions, the infants becoming adult members when they turned 18.
Sources: en.wikipedia.org
PDBsum has links to three-dimensional structures of various alcohol dehydrogenases contained in the Protein Data Bank ExPASy contains links to the alcohol dehydrogenase sequences in Swiss-Prot, to a Medline literature search about the enzyme, and to entries in other databases. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1A. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1B. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1C. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 4. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase class-3.
Somalia is a semi-arid country with about 1.6% arable land. The first local environmental organisations were Ecoterra Somalia and the Somali Ecological Society, which promoted ecological awareness and mobilised environmental programs governmentally and through grassroots efforts. From 1971 onward, a massive tree-planting campaign on a nationwide scale was introduced by the communist government to halt the advance of wind-driven sand dunes, which threatened to engulf towns, roads and farm land. By 1988, 265 hectares of a projected 336 hectares had been treated, with 39 range reserve sites and 36 forestry plantation sites established. In 1986, the Wildlife Rescue, Research and Monitoring Centre was established by Ecoterra International, with the goal of raising ecological awareness. This effort led in 1989 to a decision by the Somali government to adhere to the Convention on International Trade in Endangered Species of Wild Fauna and Flora, which banned the trade of elephant ivory. Following the tsunami of December 2004, it was alleged that Somalia's shoreline was used to dump toxic waste. The waves after the tsunami stirred up nuclear and toxic waste that was possibly dumped illegally by foreign firms.
Products include whole dried chilies, chili flakes, and chili powder, Fresh or dried chilies are used to make hot sauce, a liquid condiment—usually bottled for commercial use—that adds spice to other dishes. Dried chilies are used to make chili oil, cooking oil infused with chili.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.